SG10201608488RA - Methods of producing anamorelin hydrochloride having controlled chloride content - Google Patents

Methods of producing anamorelin hydrochloride having controlled chloride content

Info

Publication number
SG10201608488RA
SG10201608488RA SG10201608488RA SG10201608488RA SG10201608488RA SG 10201608488R A SG10201608488R A SG 10201608488RA SG 10201608488R A SG10201608488R A SG 10201608488RA SG 10201608488R A SG10201608488R A SG 10201608488RA SG 10201608488R A SG10201608488R A SG 10201608488RA
Authority
SG
Singapore
Prior art keywords
methods
chloride content
controlled chloride
anamorelin hydrochloride
producing
Prior art date
Application number
SG10201608488RA
Other languages
English (en)
Inventor
Shin-Itsu Kuwabe
Takehiko Yanagimachi
Hideyuki Yoshiyama
Groot Eleanor De
Rubio Silvina Garcia
Peter Manini
Seemon Pines
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201608488R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of SG10201608488RA publication Critical patent/SG10201608488RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG10201608488RA 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content SG10201608488RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
SG10201608488RA true SG10201608488RA (en) 2016-12-29

Family

ID=48225135

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608488RA SG10201608488RA (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content
SG11201406478XA SG11201406478XA (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201406478XA SG11201406478XA (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Country Status (47)

Country Link
US (8) US20140018391A1 (enrdf_load_stackoverflow)
EP (3) EP3517532B1 (enrdf_load_stackoverflow)
JP (3) JP6109925B2 (enrdf_load_stackoverflow)
KR (2) KR101972998B1 (enrdf_load_stackoverflow)
CN (3) CN103857669B (enrdf_load_stackoverflow)
AP (1) AP2014008013A0 (enrdf_load_stackoverflow)
AR (1) AR090725A1 (enrdf_load_stackoverflow)
AU (1) AU2013249197B2 (enrdf_load_stackoverflow)
BR (1) BR112014025972A8 (enrdf_load_stackoverflow)
CA (2) CA3031652C (enrdf_load_stackoverflow)
CL (1) CL2014002817A1 (enrdf_load_stackoverflow)
CO (1) CO7131356A2 (enrdf_load_stackoverflow)
CR (1) CR20140530A (enrdf_load_stackoverflow)
CY (1) CY1120276T1 (enrdf_load_stackoverflow)
DK (2) DK3517532T3 (enrdf_load_stackoverflow)
DO (1) DOP2014000235A (enrdf_load_stackoverflow)
EA (1) EA031581B1 (enrdf_load_stackoverflow)
EC (1) ECSP14027739A (enrdf_load_stackoverflow)
ES (2) ES2820354T3 (enrdf_load_stackoverflow)
GE (1) GEP20186902B (enrdf_load_stackoverflow)
HK (1) HK1248694A1 (enrdf_load_stackoverflow)
HR (1) HRP20180316T1 (enrdf_load_stackoverflow)
HU (2) HUE050865T2 (enrdf_load_stackoverflow)
IL (1) IL235064B (enrdf_load_stackoverflow)
JO (1) JO3353B1 (enrdf_load_stackoverflow)
LT (1) LT2838892T (enrdf_load_stackoverflow)
MA (1) MA37524B1 (enrdf_load_stackoverflow)
MD (1) MD4615C1 (enrdf_load_stackoverflow)
ME (1) ME02966B (enrdf_load_stackoverflow)
MX (1) MX354793B (enrdf_load_stackoverflow)
MY (1) MY170068A (enrdf_load_stackoverflow)
NI (1) NI201400124A (enrdf_load_stackoverflow)
NO (1) NO2877697T3 (enrdf_load_stackoverflow)
NZ (1) NZ700833A (enrdf_load_stackoverflow)
PE (1) PE20150084A1 (enrdf_load_stackoverflow)
PH (1) PH12014502351B1 (enrdf_load_stackoverflow)
PL (2) PL2838892T3 (enrdf_load_stackoverflow)
PT (2) PT3517532T (enrdf_load_stackoverflow)
RS (1) RS56869B1 (enrdf_load_stackoverflow)
SG (2) SG10201608488RA (enrdf_load_stackoverflow)
SI (2) SI3290410T1 (enrdf_load_stackoverflow)
TN (1) TN2014000421A1 (enrdf_load_stackoverflow)
TW (2) TWI677494B (enrdf_load_stackoverflow)
UA (1) UA116207C2 (enrdf_load_stackoverflow)
UY (1) UY34753A (enrdf_load_stackoverflow)
WO (1) WO2013158874A1 (enrdf_load_stackoverflow)
ZA (1) ZA201408508B (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
MA40607B1 (fr) 2014-09-04 2019-11-29 Helsinn Healthcare Sa Traitements médicaux à base d'anamoréline
KR20180030825A (ko) 2015-07-24 2018-03-26 뉴링크 제네틱스 코퍼레이션 1-메틸-d-트립토판의 염 및 프로드러그
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
CN114630655A (zh) * 2019-08-30 2022-06-14 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
WO2006016995A1 (en) 2004-06-29 2006-02-16 Sapphire Therapeutics, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
CA2677813A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
NZ700833A (en) 2016-01-29
CA2869893C (en) 2019-03-05
US20150072934A1 (en) 2015-03-12
NO2877697T3 (enrdf_load_stackoverflow) 2018-10-13
AP2014008013A0 (en) 2014-10-31
JO3353B1 (ar) 2019-03-13
US9981002B2 (en) 2018-05-29
HRP20180316T1 (hr) 2018-04-06
HUE035697T2 (en) 2018-05-28
AU2013249197B2 (en) 2017-04-06
NI201400124A (es) 2015-09-21
SI3290410T1 (sl) 2020-11-30
RS56869B1 (sr) 2018-04-30
US10905737B2 (en) 2021-02-02
MX354793B (es) 2018-03-21
EP3290410B1 (en) 2020-07-01
MD4615B1 (ro) 2019-01-31
KR20190044697A (ko) 2019-04-30
DOP2014000235A (es) 2015-01-31
CL2014002817A1 (es) 2015-08-14
MA37524B1 (fr) 2017-04-28
EA031581B1 (ru) 2019-01-31
BR112014025972A8 (pt) 2021-06-22
US20160237115A1 (en) 2016-08-18
DK2838892T3 (en) 2018-03-12
KR102141323B1 (ko) 2020-08-05
GEP20186902B (en) 2018-10-25
EP2838892B1 (en) 2017-12-06
CA3031652C (en) 2020-10-27
KR20150013115A (ko) 2015-02-04
US20140018391A1 (en) 2014-01-16
TWI677494B (zh) 2019-11-21
BR112014025972A2 (pt) 2017-06-27
JP6109925B2 (ja) 2017-04-05
CY1120276T1 (el) 2019-07-10
US10300105B2 (en) 2019-05-28
ES2820354T3 (es) 2021-04-20
EP2838892A1 (en) 2015-02-25
US20190000914A1 (en) 2019-01-03
JP6616853B2 (ja) 2019-12-04
UA116207C2 (uk) 2018-02-26
EP3517532B1 (en) 2021-10-13
US9403867B2 (en) 2016-08-02
US20160235804A1 (en) 2016-08-18
DK3517532T3 (da) 2022-01-03
US10576122B2 (en) 2020-03-03
JP2015514779A (ja) 2015-05-21
PT3517532T (pt) 2021-11-08
PH12014502351A1 (en) 2015-01-12
US9872883B2 (en) 2018-01-23
CN110041304A (zh) 2019-07-23
CA2869893A1 (en) 2013-10-24
MA37524A1 (fr) 2016-06-30
SG11201406478XA (en) 2014-11-27
KR101972998B1 (ko) 2019-04-29
HK1202863A1 (en) 2015-10-09
AR090725A1 (es) 2014-12-03
CO7131356A2 (es) 2014-12-01
JP2017101082A (ja) 2017-06-08
MY170068A (en) 2019-07-03
MX2014012178A (es) 2015-08-05
UY34753A (es) 2013-11-29
TW201348224A (zh) 2013-12-01
EA201401151A1 (ru) 2015-06-30
CN110041398A (zh) 2019-07-23
US20160229889A1 (en) 2016-08-11
US9956261B2 (en) 2018-05-01
PH12014502351B1 (en) 2015-01-12
CR20140530A (es) 2015-03-25
PE20150084A1 (es) 2015-01-23
EP3290410A1 (en) 2018-03-07
TWI589572B (zh) 2017-07-01
SI2838892T1 (en) 2018-05-31
ES2658862T3 (es) 2018-03-12
HUE050865T2 (hu) 2021-01-28
MD20140122A2 (ro) 2015-05-31
TN2014000421A1 (en) 2016-03-30
JP2018076375A (ja) 2018-05-17
PL3290410T3 (pl) 2021-01-11
MD4615C1 (ro) 2019-08-31
CN103857669B (zh) 2019-06-28
US20190231843A1 (en) 2019-08-01
WO2013158874A1 (en) 2013-10-24
PL2838892T3 (pl) 2018-05-30
HK1248694A1 (en) 2018-10-19
CA3031652A1 (en) 2013-10-24
JP6284665B2 (ja) 2018-02-28
IL235064A0 (en) 2014-12-31
TW201722928A (zh) 2017-07-01
AU2013249197A1 (en) 2014-10-30
CN103857669A (zh) 2014-06-11
ME02966B (me) 2018-07-20
IL235064B (en) 2019-09-26
EP3517532A1 (en) 2019-07-31
US20200276259A1 (en) 2020-09-03
PT2838892T (pt) 2018-02-28
ZA201408508B (en) 2020-01-29
LT2838892T (lt) 2018-03-12
ECSP14027739A (es) 2015-12-31

Similar Documents

Publication Publication Date Title
PL2892525T3 (pl) Sposoby leczenia dystrofii mięśniowej
ZA201500152B (en) Methods of treating arthritis
EP2717855A4 (en) PROCESSING METHODS
IL236644A0 (en) Methods of inducing coma
ZA201406494B (en) Methods of producing sulfilimine compounds
PL2836460T3 (pl) Sposób wytwarzania grafenu
PL2800476T3 (pl) Sposób karmienia
PL2931937T3 (pl) Sposób wytwarzania układów nanocząstek metali
ZA201408508B (en) Methods of producing anamorelin hydrochloride having controlled chloride content
GB201220155D0 (en) Method of manufacture
IL237862A0 (en) Methods to reduce the formation of scale
GB201215942D0 (en) Method of treatent
SG2013085071A (en) Method of producing methionine
ZA201503833B (en) Method of hemoglobin-f determination
GB201204603D0 (en) Method of producing knitting foam
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201212279D0 (en) Method of construction
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment